The company focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nanoparticulates, drug/device combination products, solid solutions and others.
PSI Project Management vice-president Bruce Frank said: "PSI’s business has grown to a great degree on the strength of our expanding cGMP manufacturing capabilities.
"We have worked hard to build a reputation around quality and responsiveness and are excited to help Kinex get this very important drug into the clinic."
Kinex Pharmaceuticals clinical manufacturing manager Mark Seep said: "Kinex’s selection of Particle Sciences to help advance this key product into the clinic was based on their excellent reputation, quality of their people, as well as the responsiveness and focus of their organization."
According to Kinex, KX2-361 is expected to help address the important unmet medical need of treating brain cancers for the many patients that await therapeutic advances for this serious disease.